[Federal Register Volume 69, Number 171 (Friday, September 3, 2004)]
[Notices]
[Page 53930]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-20093]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Antitumor Macrocyclic
Lactones, Compositions and Methods of Use
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR part 404.7(a)(1)(i), that the National Institutes of Health,
Department of Health and Human Services, is contemplating the grant of
an exclusive patent license to practice the inventions embodied in
International Patent Application PCT/US98/15011, all related foreign
and domestic patents and patent applications, entitled ``Antitumor
Macrocyclic Lactones, Compositions and Methods of Use'' (DHHS Ref. No.
E-244-1997/0), and in International Patent Application PCT/US00/05582,
all related foreign and domestic patents and patent applications,
entitled ``Vacuolar-Type (H+)-ATPase Inhibiting Compounds,
Compositions, And Use Thereof '' (DHHS Ref. No. E-244-1997/3), to Reata
Discovery, Inc., located in Dallas, TX. The patent rights in these
inventions have been assigned to the United States of America.
The prospective exclusive license territory will be worldwide and
the field of use may be limited to human therapeutics for the treatment
of cancer.
DATES: Only written comments and/or license applications which are
received by the National Institutes of Health on or before November 2,
2004 will be considered.
ADDRESSES: Requests for copies of the patent, inquiries, comments and
other materials relating to the contemplated exclusive license should
be directed to: George G. Pipia, PhD, Technology Licensing Specialist,
Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone:
(301) 435-5560; Facsimile: (301) 402-0220; and e-mail:
[email protected].
SUPPLEMENTARY INFORMATION: The present inventions include macrocyclic
lactones, and specifically salicylihalamides and related compounds,
which are among the classes of compounds identified from biological
sources. The NIH licensee for this technology might have some
obligations to the source-country of the biological material. The
present inventions further provide a method of preventing or treating
cancer, which comprises administration to a patient an effective
anticancer amount of at least one compound of the present invention.
Furthermore, these compounds act as vacuolar-type (H+)-ATP-
ase inhibitors and can possibly be useful for the treatment of
osteoporosis, development of drug resistance in tumor cells,
Alzheimer's disease, glaucoma, abnormal urinary acidification and
treatment or prevention of viral infections (e.g., baculoviruses and
retroviruses).
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404.7. The prospective exclusive license may be granted unless within
sixty (60) days from the date of this published notice, the NIH
receives written evidence and argument that establish that the grant of
the license would not be consistent with the requirements of 35 U.S.C.
209 and 37 CFR part 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: August 25, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 04-20093 Filed 9-2-04; 8:45 am]
BILLING CODE 4140-01-P